Slide 1: Q2 2023 Earnings
Q2 2023 Earnings AUGUST 8, 2023
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a
Slide 3: Corporate Transformation: Progress on Assay Redevelopment Roadmap
Corporate Transformation: Progress on Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 CEO transition Strategic review Stability and Manufacturing Manufacturing Continued Optimized on April 25th completed in July, variance implementation implementatio
Slide 4: LucentAD Blood Test
LucentAD Blood Test • LucentAD - first LDT test to measure ptau-181 levels in patient blood samples. Step 1 • High correlation with amyloid pathology A health care provider orders the LucentAD blood test and schedules a • Run in Quanterix’s high capacity CLIA Lab, on blood draw appointment. Simoa® p
Slide 5: NfL Reference Database Study
NfL Reference Database Study • Neurofilament light chain (NfL) is a protein that can be used to diagnose and manage neurological conditions. • Normal NfL levels can vary by age, so a reference dataset of serum NfL levels across a wide spectrum of ages is necessary. • Researchers, enabled by the Simo
Slide 6: Bio-Hermes Trial
Bio-Hermes Trial GAP Foundation first blood biomarker study • Large, multi-center, prospective, longitudinal study investigating the use of blood-based biomarkers to diagnose Alzheimer's disease • 24% of 1,000 volunteers from traditionally underrepresented communities. • 3 cohorts: Healthy, Mild Cog
Slide 7: 2023 Guidance
2023 Guidance Updated full year 2023 Revenue, Gross Margin, and Cash Burn Guidance Revenue (in millions) $105.5 $110 - $116 Full Year Revenue Expected FY 2023 Revenue between $110 to $116 million, previous guidance was $104 to $111 million. Pharma Collaboration(s) $6 ~$11 Gross Margin % Expected FY
Slide 8: Q2 2023 Results vs PYQ2
Q2 2023 Results vs PYQ2 (in millions) Q2 GAAP Q2 Non-GAAP One-Time OTHER 2022 2023 2022 2023 Strategic INSTRUMENTS CONSUMABLES UltraDx ACCELERATOR Collaborations** SERVICES Benefit* Revenue Mix 11% 49% 3% 19% 7% 11% Revenue* 23.5 31.0 23.5 31.0 Gross Margin $ 8.7 19.1 6.8 17.5 Gross Margin % 37.1% 6
Slide 9: Q2 2023 Cash
Q2 2023 Cash (in millions) -0.1 332.3 0.1 0.6 332.2 6.1 6.8 332.3 EOQ1 2023 Net Loss Non Working CAPEX End Q2 FY23 Cash Activities Capital and Others Notes: Ending total cash $332.2M is comprised of unrestricted cash balance $329.5M and restricted cash balance $2.7M. 9
Slide 10: Scientific Validation Driving Adoption
Neurology Immunology & Oncology Scientific Validation Driving Adoption Infectious Disease & Others INSTRUMENTS ACCELER ATOR* PUBLICATIONS BIOMARKERS Placements Projects & Revenue # of units placed Cumulative Cumulative Cumulative $m Revenue 177 168 2,407 551 930 Number of Drug 538 Trial Projects 149
Slide 11: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 GAAP gross profit $ 19,138 $
Slide 12: AUGUST 8, 2023
AUGUST 8, 2023